Lonza completes acquisition of Cambrex bio businesses

Published: 8-Feb-2007
Ingredients Pharmaceutical

Swiss group Lonza has completed the acquisition of Cambrex's Bioproducts and Biopharma subsidiaries. The sale was approved by an overwhelming majority of Cambrex shareholders, at a Special Meeting held this week.


Swiss group Lonza has completed the acquisition of Cambrex's Bioproducts and Biopharma subsidiaries. The sale was approved by an overwhelming majority of Cambrex shareholders, at a Special Meeting held this week.

The Microbial Biopharmaceuticals business will be integrated into the Lonza Biopharmaceuticals business. The Research Bioproducts will be positioned as a stand-alone business unit and renamed as Lonza Bioscience. Its leading position in cell-based research, endotoxin detection and cell therapy manufacturing complements Lonza's Biopharmaceuticals business.

Lonza will immediately start integrating the two Cambrex units and its approximately 1000 employees into the existing structure of the company.

Meanwhile, Cambrex, alife sciences company with operations in the US and Europe, will concentrate resources on the pharmaceutical products and services business, said Cambrex chairman James Mack.

  • Companies:
  • Lonza
See more

You may also like

Manufacturing

Lonza launches Design2Optimise platform to streamline API development

Read more
The Design2Optimise platform contributes to improved efficiencies and timelines to clinical trials of small molecule APIs

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  3. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  4. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  5. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Lonza launches Design2Optimise platform to streamline API development

The Design2Optimise platform contributes to improved efficiencies and timelines to clinical trials of small molecule APIs
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Manufacturing

Lonza's Oregon site adds bottling and labelling capabilities in strategic upgrade

The company is now able to offer tablet and capsule bottling equipment, which can provide medicines to early-phase clinical trials
Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Leucid Bio chooses Lonza automated personalised CAR T-Cells platform

Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralised manufacturing model
Subscribe now